This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
by Zacks Equity Research
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
AMGNNegative Net Change LGNDNegative Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechs
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
BIIBNegative Net Change LGNDNegative Net Change HRTXNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
by Sundeep Ganoria
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
RHHBYNegative Net Change AMGNNegative Net Change ALTNegative Net Change VKTXNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
LGNDNegative Net Change ANIPNegative Net Change KODNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
by Zacks Equity Research
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
LGNDNegative Net Change VNDANegative Net Change ANIPNegative Net Change ENTXPositive Net Change
biotechs
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
by Zacks Equity Research
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
RHHBYNegative Net Change NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
by Zacks Equity Research
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
BMYNegative Net Change LGNDNegative Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
by Zacks Equity Research
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
BIIBNegative Net Change LLYNegative Net Change
biotechs
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
by Zacks Equity Research
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
by Zacks Equity Research
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
LGNDNegative Net Change ANIPNegative Net Change HRTXNegative Net Change ASNDNegative Net Change
biotechs medical
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
by Zacks Equity Research
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
UTHRNegative Net Change LGNDNegative Net Change ANIPNegative Net Change ALLONegative Net Change
biotechs cell-therapy earnings medical pharmaceuticals
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
by Zacks Equity Research
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
NVONegative Net Change LGNDNegative Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
by Zacks Equity Research
Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
REGNNegative Net Change JNJNegative Net Change BAYRYNegative Net Change LGNDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
by Zacks Equity Research
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs earnings medical vaccines
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
by Zacks Equity Research
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
GSKNegative Net Change PFENegative Net Change MRNANegative Net Change LGNDNegative Net Change
biotechs
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
AZNNegative Net Change BMYNegative Net Change MRKNegative Net Change LGNDNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
by Zacks Equity Research
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
VRTXNegative Net Change HTGCNegative Net Change CRSPNegative Net Change
biotechs earnings gene-therapy pharmaceuticals
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
NKTRPositive Net Change LGNDNegative Net Change ANIPNegative Net Change
biotechs
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.
REGNNegative Net Change NTLAPositive Net Change ENTXPositive Net Change
biotechs earnings
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
by Zacks Equity Research
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
UTHRNegative Net Change LGNDNegative Net Change INSMNegative Net Change ANIPNegative Net Change
biotechs earnings medical
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
by Zacks Equity Research
Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
UTHRNegative Net Change LGNDNegative Net Change ANIPNegative Net Change IOVANegative Net Change
biotechs cell-therapy medical
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
by Zacks Equity Research
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
LGNDNegative Net Change FOLDNegative Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXNegative Net Change ANIPNegative Net Change XENENegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
by Zacks Equity Research
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
VRTXNegative Net Change LGNDNegative Net Change EDITNegative Net Change ENTXPositive Net Change
biotechs earnings
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
RHHBYNegative Net Change BMYNegative Net Change NVONegative Net Change PRTANegative Net Change
biotechnology biotechs earnings pharmaceuticals